Gabapentin for Pain Management after Major Surgery: A Placebo-controlled, Double-blinded, Randomized Clinical Trial (the GAP Study)
Authors' conclusion
Among patients undergoing major cardiac, thoracic, and abdominal surgery, adding gabapentin to multimodal analgesic regimes did not alter the length of hospital stay or the number of serious adverse events.
Study context
- Population
- Adults undergoing major cardiac, thoracic or abdominal surgeryrandomised
- Participants
- 1,196 adults
- Comparison
- Gabapentin vs placebo
- Gabapentinn = 600
- Placebon = 596reference
- Primary endpoint
- Hospital LOS
Methodological detailsmulticentre, double-blinded, placebo-controlled
- Multicentre
- Double-blinded
- Placebo-controlled
Primary result
As reported in the abstract
Hazard ratio
1.07
95% CI 0.95–1.20
P = 0.26
By group
Gabapentin vs Placebo
HR 1.07 (95% CI 0.95–1.20); P = 0.26
Safety
≥1 serious adverse event
- ≥1 serious adverse event: 384 participants overall; some variation across surgical specialties
Original publication
Gabapentin for Pain Management after Major Surgery: A Placebo-controlled, Double-blinded, Randomized Clinical Trial (the GAP Study). Anesthesiology. Published 15 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →